Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 8/20 | 0.36 |
| ▸ | TP53 | P04637 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034145 | 0.88 | MAPT (0.40) | CFTRMAPTTP53SMN1; SMN2MGLL | |
| SCHEMBL15023304 | 0.84 | CFTR (0.39) | CFTRMAPTTP53SMN1; SMN2MGLL | |
| SCHEMBL15034128 | 0.84 | CFTR (0.42) | CFTRMAPTTP53SMN1; SMN2MGLL | |
| SCHEMBL15034351 | 0.84 | CFTR (0.37) | CFTRMAPTTP53SMN1; SMN2MGLL | |
| SCHEMBL15034224 | 0.83 | CFTR (0.36) | CFTRMAPTTP53SMN1; SMN2MGLL | |
| SCHEMBL15034121 | 0.83 | IRAK4 (0.37) | CFTRMAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL15034154 | 0.82 | MGLL (0.39) | CFTRMAPTTP53SMN1; SMN2MGLL | |
| SCHEMBL15034129 | 0.82 | CFTR (0.39) | CFTRMAPTTP53SMN1; SMN2MGLL | |
| SCHEMBL15034134 | 0.81 | CFTR (0.44) | CFTRMAPTTP53SMN1; SMN2MGLL | |
| SCHEMBL15034076 | 0.80 | SLC6A7 (0.39) | CFTRMAPTTP53MGLLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158042-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158042-A1 | NOVEL COMPOUNDS | GRM5, GRIK5, GRM1 | CFTR 3753/4885MAPT 270/4885TP53 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.